These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

717 related items for PubMed ID: 19200870

  • 1. New options for early treatment of multiple sclerosis.
    Tintoré M.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S9-S11. PubMed ID: 19200870
    [Abstract] [Full Text] [Related]

  • 2. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B.
    Rev Neurol (Paris); 2008 Nov 01; 164(11):917-26. PubMed ID: 18790510
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Early treatment: PreCISe-ly what the patient needs.
    Montalban X.
    J Neurol Sci; 2009 Dec 01; 287 Suppl 1():S2-6. PubMed ID: 20106344
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The use of glatiramer acetate in the treatment of multiple sclerosis.
    Wolinsky JS.
    Adv Neurol; 2006 Dec 01; 98():273-92. PubMed ID: 16400839
    [Abstract] [Full Text] [Related]

  • 7. Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution.
    Rovaris M, Gambini A, Gallo A, Falini A, Ghezzi A, Benedetti B, Sormani MP, Martinelli V, Comi G, Filippi M.
    Neurology; 2005 Nov 22; 65(10):1626-30. PubMed ID: 16301492
    [Abstract] [Full Text] [Related]

  • 8. Lessons from randomised direct comparative trials.
    Achiron A, Fredrikson S.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T, Bereczki D.
    Ideggyogy Sz; 2004 Nov 20; 57(11-12):401-16. PubMed ID: 15662768
    [Abstract] [Full Text] [Related]

  • 11. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.
    Cohen JA, Rovaris M, Goodman AD, Ladkani D, Wynn D, Filippi M, 9006 Study Group.
    Neurology; 2007 Mar 20; 68(12):939-44. PubMed ID: 17372130
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.
    Johnson KP.
    Expert Rev Neurother; 2012 Apr 20; 12(4):371-84. PubMed ID: 22449210
    [Abstract] [Full Text] [Related]

  • 14. Non-specific immunosuppressants in the treatment of multiple sclerosis.
    Confavreux C, Vukusic S.
    Clin Neurol Neurosurg; 2004 Jun 20; 106(3):263-9. PubMed ID: 15177781
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD.
    Neurology; 2009 Jun 09; 72(23):1976-83. PubMed ID: 19279320
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Glatiramer: new preparation. No place in multiple sclerosis.
    Prescrire Int; 2004 Feb 09; 13(69):10-2. PubMed ID: 15055208
    [Abstract] [Full Text] [Related]

  • 19. The effectiveness of glatiramer acetate in clinical practice: an observational study.
    Fernández-Fernández Ó, Garcia-Trujillo L, Guerrero-Fernández M, León A, López-Madrona JC, Alonso A, Bustamante R, Fernández-Sánchez VE.
    Rev Neurol; 2012 Jan 01; 54(1):1-9. PubMed ID: 22187206
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.